+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Liver Cancer (Hepatocellular Carcinoma): Disease and Pipeline Analysis

  • ID: 2739738
  • Report
  • April 2013
  • 60 Pages
  • Industry Standard Research (ISR)
1 of 5
This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the hepatocellular carcinoma (liver cancer) market not available elsewhere. The purpose of this report is to give an extensive overview of the current and future liver cancer market, the activities of the key market players and the issues surrounding drug development.
Note: Product cover images may vary from those shown
2 of 5


3 of 5
Copyright and Usage Guidelines
Table of Abbreviations
Table of Definitions

Chapter 1 Hepatocellular Carcinoma Overview

Chapter 2 Commercial Rationale
High Unmet Need and Limited Available Therapies
Increasing HCC Incidence
Orphan Disease Status
Active Drug Development Field

Chapter 3 Environmental Analysis
Disease Epidemiology
Major Markets Environmental Analysis
Emerging Markets Environmental Analysis
Additional Countries

Chapter 4 Clinical Development Pipeline
R&D Trends in the Treatment of Primary Liver Cancer
Late Phase Development Pipeline
Aptocine (talaporfin sodium), Light Sciences Oncology
Everolimus, Novartis
Muparfostat, Medigen Biotech
ADI-PEG20, Polaris Group
Ramucirumab (IMC-1121B), Lilly (Imclone)
Tivantinib (ARQ197), ArQule and Daiichi Sankyo
Regorafenib (BAY73-4506), Bayer
Orantinib (TSU-68), Taiho Pharma
Peretinoin (NIK-333), Kowa
Resminostat, 4SC Ag
Early Phase Development Pipeline

Chapter 5 Clinical Trial Environment

Chapter 6 Country Profiles
United States
United Kingdom
South Korea
About Industry Standard Research

List of Tables

Table 1 HCC Life Expectancy by Disease Stage
Table 2 BCLC HCC Classification
Table 3 AJCC HCC Classification
Table 4 Summary of SHARP Trial Results
Table 5 Percent of HCC Cases Linked to Risk Factors by Region
Table 6 Primary Liver Cancer - Major Markets Patient Population and Product Environment
Table 7 Primary Liver Cancer - Emerging Markets Patient Population and Product Environment
Table 8 The Late Phase HCC Pipeline
Table 9 Overview of LitX
Table 10 Overview of Everolimus
Table 11 Overview of Muparfostat
Table 12 Overview of ADI-PEG20
Table 13 Overview of Ramucirumab
Table 14 Overview of Tivantinib
Table 15 Overview of Regorafenib
Table 16 Overview of Orantinib
Table 17 Overview of Resminostat
Table 18 Early Phase HCC Development Pipeline
Table 19 HCC Trials by Development Phase and Sponsor Type
Table 20 Ongoing, Industry Sponsored HCC Trials
Table 21 Recently Completed, Industry Sponsored HCC Trials
Table 22 Ongoing, All Sponsors HCC Trials
Table 23 Recently Completed, All Sponsors HCC Trials

List of Figures

Figure 1 Global Prevalence of Hepatitis B
Figure 2 Global Distribution of Hepatitis C
Figure 3 Countries with the Highest Populations of HCC Patients (2008)
Note: Product cover images may vary from those shown
4 of 5
This report provides the pharmaceutical industry with a therapeutic assessment, pipeline analysis, and unique insight into the current clinical trial environment for the hepatocellular carcinoma (HCC) market.

“HCC is the fifth most common cancer diagnosed globally in men, is the third most common cause of cancer death, and because only one systemic therapy is available, remains a highly underserved disease,” explained Andrew Schafer, President of ISR. “With high incidence and morbidity rates and a lack of available effective therapies, significant commercial opportunity exists for this orphan drug class.”

To support this opportunity, ISR’s newest report provides a thorough disease overview, discusses major and emerging markets, and compiles an analysis of ongoing and recently completed HCC trials registered on ClinicalTrials.gov to shed light on trial activity (reported in aggregate and by industry sponsors).

“With this report, sponsors can learn how products in the pipeline could compete in this market, identify strategic development opportunities, plan global clinical trial and market access strategies, and assess the competition with a full analysis of companies participating in this market,” Schafer explained.

Additionally, ISR’s report provides a thorough analysis of 10 products currently in early and late phase development that could result in promising new therapies.

“Signal transduction pathways involved in tumor cell proliferation, resistance to apoptosis, stimulation of angiogenesis, invasiveness, and metastasis have been implicated in HCC and, therefore, are interesting targets for new therapies,” Schafer explained.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown